-

ABOzymes Is Now “AVIVO” – A New Identity for Future Growth

VANCOUVER, British Columbia--(BUSINESS WIRE)--Today, ABOzymes has unveiled a new identity, including a new name - “Avivo”. The update reflects the evolution of the Company since its founding in 2020 while maintaining the Company’s founding vision – to create a world where blood type is no longer the first constraint in accessing life-saving organ transplants or blood transfusions.

The new name takes the prefix “a”, which means “from or for,” and “vivo”, which means “life” - together Avivo means “from life, for life”. A corresponding brand has been created to convey both the freshness and maturity of the company. With a goal to improve patient lives, the new identity conveys a hopeful outlook: a “second chance at life”.

“While the ABOzymes brand has served us well, our research and audience discovery has told us a new name and brand as strong as our science is required to better express our evolving story and direction,” said John Coleman, President and CEO of Avivo.

The rebrand to Avivo also includes a new website designed to address broad stakeholder interests and includes a new video highlighting how Avivo is reimagining what’s possible when we eliminate blood type constraints.

About Avivo

Avivo, a British Columbia-based preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. This innovative platform enables a world where a person’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Avivo’s platform will enable healthcare providers to better prioritize patients by medical urgency, spend less on management and logistics and ultimately save more lives. For more information, please visit: www.avivobio.com.

Contacts

Jason Kinnear
jason@venture4thnow.com
647-291-8026

Industry:

Avivo

Release Versions
English

Contacts

Jason Kinnear
jason@venture4thnow.com
647-291-8026

More News From Avivo

World’s First Blood Type A-to-O Kidney Transplant Achieved by Avivo and UBC Researchers

VANCOUVER, British Columbia--(BUSINESS WIRE)--In a world-first, researchers have successfully transplanted a donor kidney after converting it from blood type A to the universal type O, removing one of the biggest barriers in organ donation: blood-type compatibility. The landmark study, published in Nature Biomedical Engineering, was led by Dr. Turun Song at West China Hospital in Chengdu, in partnership with the University of British Columbia (UBC) and Vancouver-based Avivo Biomedical Inc. (Avi...

Avivo Biomedical Inc. Appoints Rob Carroll MD as Chief Medical Officer

VANCOUVER, British Columbia--(BUSINESS WIRE)--Avivo Biomedical Inc. (‘Avivo’, avivobio.com), a leading innovator in blood type conversion for organ transplantation and blood transfusion applications, is pleased to announce the appointment of Rob Carroll MD, DM (Oxon), FRACP, A(ACHI) as its new Chief Medical Officer (CMO). Dr. Rob Carroll brings an extraordinary depth of expertise to Avivo, combining over two decades of leadership in transplant medicine, nephrology, and immunogenetics. As a tran...

Avivo Biomedical Inc. enters into know-how agreement with Mayo Clinic for advancement of blood type conversion technology for organ transplants

VANCOUVER, British Columbia--(BUSINESS WIRE)--Avivo Biomedical Inc. (“Avivo”), a British Columbia-based preclinical-stage company, proudly announces a collaboration with Mayo Clinic through a know-how license agreement centering on Avivo's technology for Enzyme-Converted type O (“ECO”) organs that is intended to improve the utilization of donor organs for transplantation. Avivo's proprietary enzyme system converts the blood type of human cells to Type-O, the universal donor type. This technolog...
Back to Newsroom